Trending
Stocks.org
You are at:»»Drug Stocks Catching Investors Interest: Generex Biotechnology (GNBT), Valeant Pharmaceuticals Intl (VRX), Acura Pharmaceuticals (NASDAQ:ACUR), Alkermes Plc (ALKS)

Drug Stocks Catching Investors Interest: Generex Biotechnology (GNBT), Valeant Pharmaceuticals Intl (VRX), Acura Pharmaceuticals (NASDAQ:ACUR), Alkermes Plc (ALKS)

762
By on Us News

Generex Biotechnology Corporation (OTCMKTS:GNBT) announced yesterday about the publication of studies investigating biomarkers related with overall survival among prostate cancer patients, who undergo treatment with the company’s immunotherapeutic agent AE37. On last trading day Generex Biotechnology Corporation (OTCMKTS:GNBT) ended up 1.25% higher to close at $0.0405 while trading in the range of $0.04 – $0.04. Its return on assets (ROA) is -102.37% while return on investment (ROI) is -155.29.

Stock analysts at TD Securities lifted their price target on shares of Valeant Pharmaceuticals International Inc (NYSE:VRX) from C$135.00 to C$145.00 in a report issued on Friday, Analyst Ratings News reports. The firm currently has a “hold” rating on the stock. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) in last trading activity ended up at $146.23 with day range of $143.98 – $147.02. Company weekly performance is 0.81% while its quarterly performance stands at 33.39%. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is -4.49% away from its 52 week high.

Acura Pharmaceuticals (NASDAQ:ACUR) issued its quarterly earnings data on Monday. The company reported ($0.29) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.06) by $0.23, Analyst RN reports. Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) belongs to Healthcare sector with market capitalization of 87.95 M and has 1.40% insider ownership. In last trading activity company’s stock closed at $1.82 while opening price was $1.90.

Analysts at Mizuho upped their price objective on shares of Alkermes Plc (NASDAQ:ALKS) from $33.00 to $56.00 in a research report issued to clients and investors on Friday, AnalystRatings.NET reports. The firm currently has a “neutral” rating on the stock. On Tuesday shares of Alkermes Plc (NASDAQ:ALKS) opened at $47.68 and closed at $47.88. This year Company’s Earnings per Share (EPS) growth is 118.20% and next year’s estimated EPS growth is 33.41%. Analysts mean target price for Alkermes Plc (NASDAQ:ALKS) is $49.30.

Get Free Updates and Stock Alerts!



*We only send one email per week
Share.

Related Posts

Get Winning Stock Alerts!

Our track record speaks for itself! Our last 7 alerts have delivered combined gains in excess of 300% and there are no signs of slowing down. Join UltimateStockAlerts.com now before you miss out on our next big runner!

We will never sell or share your information.
Close